NewsRoom Articles - BioMedWire (BMW)

ThursdayJun 11, 2026 10:00 am

FIU Researchers Discover New Way of Extending Immune Cell Lifespan and Effectiveness

CAR-T therapy has been transformational in treating many blood cancers, such as leukemia and lymphoma. However, this treatment approach hasn’t worked for solid tumors, and it also reaches a point and becomes ineffective in blood cancers. A new study just found a way to boost the lifespan and efficacy window of these important immune cells that help fight cancer. The study, whose findings appeared in the journal Frontiers in Immunology, was conducted by a team at Florida International University (FIU). The researchers spent about five years studying why cancer-fighting immune cells lose their effectiveness and don’t survive for long. They were particularly interested in establishing how tumor cells develop a protective mechanism against the immune cells…

ThursdayJun 11, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market. Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”). VERAXA Biotech has successfully concluded a business combination…

WednesdayJun 10, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Is ‘One to Watch’

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies. Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has…

TuesdayJun 09, 2026 10:00 am

Hospitals Take the Lead in Tackling Health Care Access and Affordability

Hospitals have come under the spotlight as public concern about the health care cost crisis reaches unprecedented levels. The president of the American Hospital Association (AHA) wrote an article last week outlining how hospitals are taking steps to ensure that access and affordability issues are addressed so that Americans can continue to enjoy the high quality of care that they have come to expect from the health care system. Rick Pollack explained that hospitals face numerous challenges, such as having to absorb a sizeable fraction of the increasing cost of providing medical services to Americans. This comes as reimbursements for programs like Medicare and Medicaid haven’t risen…

MondayJun 08, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body. The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated. Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food…

FridayJun 05, 2026 10:30 am

Oncotelic Therapeutics Inc. (OTLC) Combines Nanomedicine, AI, and Robotics to Advance Precision Oncology and Rare Disease Innovation

OTLC continues to advance its Deciparticle nanomedicine platform, with expanding international development initiatives supporting future therapeutic and commercial opportunities. The company’s PDAOAI ecosystem now incorporates 28 million scientific abstracts and is being deployed into real-world pharmaceutical automation applications through TechForce Robotics. The company is leveraging AI, nanomedicine, and automation to accelerate therapies for cancer and rare diseases. Oncotelic Therapeutics (OTCQB: OTLC) is strategically placing itself at the nexus of precision oncology, advanced automation, and artificial intelligence. Through its PDAOAI artificial intelligence ecosystem, Deciparticle(TM) nanomedicine platform, and emerging robotics initiatives, the company is quickly building an integrated technology portfolio built to improve…

FridayJun 05, 2026 10:00 am

LA Calls for Infectious Diseases Vigilance During World Cup

This month and in July, the SoFi Stadium in Los Angeles County will host several World Cup matches, and other tournament-related activities will take place within the county. Accordingly, the health department of the county has put health care providers on notice to be alert for infectious diseases during the tournament. SoFi Stadium will host eight World Cup matches, and the global tournament is coinciding with Pride Month. Because of these events, lots of national and international travelers, at least 150,000, are expected to descend on LA County, and that could provide ideal conditions for many infectious diseases to spread. County health officials warn that the massive…

FridayJun 05, 2026 9:45 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples. The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points. Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges. Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings. The global alcohol and drug testing devices market is…

ThursdayJun 04, 2026 10:00 am

Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding

Scientists have identified a potential mechanism through which aggressive pediatric brain tumors called diffuse midline gliomas spread. The researchers found that immune cells within the brain, called microglia, produce proteins called fibronectin that help the tumors to progress. The findings, published in the Cell Death & Disease journal, offer a possible mechanism that can be targeted in efforts to develop effective treatments against these tumors. Conducted by a team at Karolinska Institutet, the researchers aimed to investigate what role microglia played in tumor progression and how these cells are impacted by the cancer. In their study, the team found that when microglia are exposed to diffuse midline glioma (DMG) cells, they respond by producing large quantities of fibronectin and…

ThursdayJun 04, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?

Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution. Pivotal FDA enrollment, manufacturing scale-up, physician engagement initiatives and CE Mark status position the company toward multiple potential value-inflection milestones. Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The…